Daily Stock Analysis, ARDM, Aradigm Corp, priceseries

Aradigm Corp. Daily Stock Analysis
Stock Information
Open
0.31
Close
0.12
High
0.35
Low
0.07
Previous Close
0.46
Daily Price Gain
-0.34
YTD High
0.80
YTD High Date
Jan 22, 2019
YTD Low
0.07
YTD Low Date
Feb 19, 2019
YTD Price Change
-0.25
YTD Gain
-67.57%
52 Week High
2.33
52 Week High Date
Jun 20, 2018
52 Week Low
0.07
52 Week Low Date
Feb 19, 2019
52 Week Price Change
-1.09
52 Week Gain
-90.08%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 17. 2017
0.97
Jun 23. 2017
1.44
26 Trading Days
48.79%
Link
LONG
Sep 20. 2017
1.50
Oct 23. 2017
4.62
23 Trading Days
207.76%
Link
LONG
Dec 7. 2017
4.18
Jan 2. 2018
5.70
16 Trading Days
36.42%
Link
LONG
Mar 9. 2018
1.18
Mar 20. 2018
1.25
7 Trading Days
6.35%
Link
LONG
Apr 10. 2018
1.29
Apr 23. 2018
1.54
9 Trading Days
18.57%
Link
LONG
Jun 1. 2018
1.46
Jun 21. 2018
1.70
14 Trading Days
16.45%
Link
LONG
Oct 2. 2018
1.18
Oct 10. 2018
1.30
6 Trading Days
9.95%
Link
Company Information
Stock Symbol
ARDM
Exchange
NasdaqCM
Company URL
http://www.aradigm.com
Company Phone
5102659000
CEO
Igor Gonda
Headquarters
California
Business Address
3929 POINT EDEN WAY, HAYWARD, CA 94545
Sector
-
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0001013238
About

Aradigm Corp. is a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Aradigm was founded in 1991 and is headquartered in Hayward, CA.

Description

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. The company's lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). It is conducting a Phase III clinical trials with Pulmaquin in BE; and Phase IIb trial with Lipoquin and Pulmaquin in BE. The company has also completed a Phase IIa trial with Lipoquin in CF and Phase IIa trial with Lipoquin in BE. Its proprietary program under development is ARD-1600 Inhaled Nicotine, a smoking cessation therapy. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.